In this episode, Professor Stavros Konstantinides talks about the prevention of recurrent events in patients with venous thromboembolism, Dr Phil Wells explains the pooled analysis of EINSTEIN EXT and EINSTEIN CHOICE and what it tells us about which patients are suitable for extended anticoagulation and Dr Jeff Weitz and Dr Jan Beyer-Westendorf discuss whether a patient treated for pulmonary embolism would be a candidate for extended anticoagulation.

Further details:

• Data on the risk of recurrent VTE after the discontinuation of anticoagulation therapy can be accessed here: https://haematologica.org/article/view/4325 • The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism developed in collaboration with the ERS can be found here: https://academic.oup.com/eurheartj/article/41/4/543/5556136 • The pooled analysis of EINSTEIN CHOICE and EINSTEIN EXTENSION is available here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894264/ • The EINSTEIN CHOICE paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1700518 • The EINSTEIN EXTENSION paper can be accessed here: https://www.nejm.org/doi/10.1056/NEJMoa1007903?url_ver=Z39.88-2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed • Data showing the increased case fatality rate of PE compared with DVT can be found in this publication: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1538-7836.2007.02450.x • Data on the increased risk of VTE recurrence in males versus females can be found here: https://www.bmj.com/content/342/bmj.d813#:~:text=Conclusions-,In%20patients%20with%20a%20first%20unprovoked%20venous%20thromboembolism%2C%20men%20have,had%20hormone%20associated%20venous%20thromboembolism. • Data supporting the increased risk of PE versus DVT recurrence in a patient with a previous PE can be found in this publication: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544622/#:~:text=However%2C%20PE%20patients%20are%20three,be%20low%20in%20these%20patients. • For anticoagulant dosing information, see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc)

Recording approval code: PP-M_RIV-ALL-0159-1; Shownotes approval code: PP-M_RIV-ALL-0160-1